Studies On A Novel Human Cardiospecific Transcription Factor And Its Involvement In Omi/htra2 Mediated Cell Death by Balakrishnan, Meenakshi Puthucode
University of Central Florida 
STARS 
Electronic Theses and Dissertations, 2004-2019 
2010 
Studies On A Novel Human Cardiospecific Transcription Factor 
And Its Involvement In Omi/htra2 Mediated Cell Death 
Meenakshi Puthucode Balakrishnan 
University of Central Florida 
 Part of the Medical Sciences Commons 
Find similar works at: https://stars.library.ucf.edu/etd 
University of Central Florida Libraries http://library.ucf.edu 
This Doctoral Dissertation (Open Access) is brought to you for free and open access by STARS. It has been accepted 
for inclusion in Electronic Theses and Dissertations, 2004-2019 by an authorized administrator of STARS. For more 
information, please contact STARS@ucf.edu. 
STARS Citation 
Balakrishnan, Meenakshi Puthucode, "Studies On A Novel Human Cardiospecific Transcription Factor And 
Its Involvement In Omi/htra2 Mediated Cell Death" (2010). Electronic Theses and Dissertations, 
2004-2019. 1590. 
https://stars.library.ucf.edu/etd/1590 
STUDIES ON A NOVEL HUMAN CARDIOSPECIFIC 
TRANSCRIPTION FACTOR AND ITS INVOLVEMENT 
IN OMI/HTRA2 MEDIATED CELL DEATH 
 
 
MEENAKSHI PUTHUCODE BALAKRISHNAN 
MSc. (Hons) Biological Sciences 
Birla Institute of Technology and Sciences (2006) 
 
 
 
 
 
A dissertation submitted in partial fulfillment of the requirements 
for the degree of Doctor of Philosophy 
in the Burnett School of Biomedical Sciences 
in the College of Medicine 
at the University of Central Florida 
Orlando, Florida 
 
 
 
 
 
Fall Term  
 
2010 
 
 
Major Professor: Antonis S. Zervos
ii 
 
ABSTRACT 
Omi/HtrA2 is a mitochondrial serine protease that is known to translocate to the cytoplasm upon 
induction of apoptosis and to activate caspase-dependent and caspase-independent cell death.  
The molecular mechanism of Omi/HtrA2’s function is not clear but involves degradation of 
specific substrates.  These substrates include cytoplasmic, mitochondrial, as well as nuclear 
proteins.  We have isolated a new Omi/HtrA2 interactor, the THAP5 protein.  THAP5 is a fifth 
member of a large family of transcription factors that are involved in cell proliferation, apoptosis, 
cell cycle control, chromosome segregation, chromatin modification and transcriptional 
regulation.  THAP5 is an approximately 50kDa nuclear protein, with a restricted pattern of 
expression.  Furthermore, there is no mouse or rat homolog for this protein.  THAP5 mRNA is 
highly expressed in the human heart but some expression is also seen in the brain and skeletal 
muscle.  The normal function of THAP5 in the heart or heart disease is unknown.  THAP5 
protein level is significantly reduced in the myocardial infarction (MI) area in the heart of 
patients with coronary artery disease (CAD).  This part of the heart sustains most of the cellular 
damage and apoptosis.  Our data clearly show that THAP5 is a specific substrate of the 
proapoptotic Omi/HtrA2 protease and is cleaved and removed during cell death.  The molecular 
mechanism of THAP5’s function is unclear.  THAP5 can bind to a specific DNA sequence and 
repress transcription of a reporter gene.  Our work suggests that THAP5 is a tissue specific 
transcriptional repressor that plays an important role in the normal function of the human heart as 
well as in the development of heart disease.  
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CHAPTER 1: GENERAL INTRODUCTION 
Omi/HtrA2 is a serine protease and a homolog of the bacterial high temperature requirement A 
(HtrA/DegP) protein [1].  It was originally identified as an interactor of Mxi2, an alternatively 
spliced form of p38 stress activated kinase, using the yeast two-hybrid system [1].  It was also 
isolated independently as an interactor of Presenilin-1 (PS-1) by another group [2].  Full-length 
Omi is a nuclear encoded 458 amino acid protein, which is designated into the following 
domains; mitochondrial targeting sequence (MTS) at its amino terminus, a transmembrane 
segment (TM), inhibitor of apoptosis protein (IAP) binding motif (IBM), serine protease domain 
and a PDZ domain at the carboxyl terminus [1-4].  Omi undergoes autocatalysis at Ala133 
thereby removing the amino terminal region including the MTS and TM domains and exposing 
the IBM (AVPS) motif.  The IBM motif is very similar to Drosophila IAP inhibitor proteins 
Reaper, Hid and Grim and their mammalian counterpart Smac/DIABLO [4-8].  The figure below 
sows full length Omi/HtrA2 and its autocatalytic processing. 
 
 
 
Figure 1: Schematic Diagram of Omi/HtrA2 and its N-terminal processing 
Upon induction of apoptosis, Omi/HtrA2 gets released into the cytoplasm where it binds to IAPs 
and proteolytically degrades them, thereby activating the caspase cascade and apoptosis [4, 5].  
In addition, it can also activate caspase independent apoptosis that involves its proteolytic 
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activity [8].  Homotrimerization of Omi/HtrA2 has been shown to be essential for the protease 
activity in addition to the presence of the PDZ domain that plays a regulatory role in protein-
protein interactions [3].  Omi/HtrA2 is predominantly present in the mitochondrial 
intermembrane space (IMS), but it has also been found in the endoplasmic reticulum (ER) and 
nucleus [1, 2, 9, 10]. The mechanism of its pro-apoptotic activity involves interaction and 
degradation of specific substrates that includes mitochondrial, cytoplasmic and nuclear proteins.  
The cytoplasmic interacting proteins of Omi/HtrA2 include Inhibitor of Apoptosis proteins 
(IAPs) such as XIAP, cIAP1, cIAP2, Apollon/Bruce, PED/PEA15, and receptor-interacting 
protein RIP1 [11-14]. The nuclear interactors include Grim-19, WARTS, p73, and Wilms’ 
Tumor Suppressor protein (WT1) [9, 15-17].  Several of these interactions are mediated via the 
PDZ domain and the protease activity of Omi/HtrA2 is always necessary and required for its pro-
apoptotic function.  The table below summarizes some of the known substrates and interactors of 
Omi reported so far.   
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Table 1: List of known interactors of Omi/HtrA2 
Protein Localization Function References 
cIAP1, cIAP2, 
XIAP, 
Apollon/Bruce 
Cytosol Inhibitor of apoptotic proteins [11, 13, 14] 
Ped/Pea15 Cytosol Antiapoptotic protein [12] 
Rip1 Cytosol Apoptosis, TNF-a signaling [13] 
EndoG Mitochondria Endonuclease proapoptotic 
protein 
[18] 
Presenilin-1,APP,            
-secretase 
Mitochondria Precursors of b amyloid 
senile plaques 
[21, 22, 23] 
Hax-1 Mitochondria Antiapoptotic protein [36] 
P73 Nucleus Tumor Suppressor, p53 
family of proteins 
[17] 
WARTS Nucleus Tumor Suppressor, G1/S cell 
cycle block 
[9] 
Grim-19 Nucleus/ 
Cytoplasm 
Apoptotic protein [16] 
WT1 Nucleus Transcription factor/tumor 
suppressor 
[15] 
THAP5 Nucleus Transcription factor/ Cell 
Cycle (G2/M block) 
[71] 
Function of Omi/HtrA2 in the mitochondria 
It is to be noted that the pro-apoptotic function of Omi/HtrA2 comes to play when it is released 
into the cytoplasm from the mitochondria.  However, while confined in the mitochondria 
Omi/HtrA2 seems to have yet another function distinct from its pro-apoptotic activity.  The other 
function of Omi/HtrA2 in mitochondria is not yet known, but it is speculated to play a role in cell 
survival thereby contributing to maintenance of mitochondrial homeostasis [19].  Disturbance of 
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this function is linked to the development of several disorders including neurodegeneration and 
tumors.  
A single missense mutation Ser276Cys in the protease domain of Omi/HtrA2 results in Motor 
Neuron Degeneration2 (Mnd2) disease in mice [19, 20]. Mnd2 homozygous mice display 
striking similarities with Parkinson’s disease (PD) phenotype such as lack of bodily 
coordination, reduced motility and tremor.  They also suffer from muscle wasting, 
neurodegeneration, significant reduction in the size of organs such as heart, kidneys, spleen and 
thymus and death within 40 days of birth [20].  A similar phenotype results in Omi/HtrA2 
knockout mice as well [19]. The loss of Omi/HtrA2 has been shown to result in the selective loss 
of striatal neurons, accumulation of unfolded proteins in mitochondria, disruption of 
mitochondrial respiration and also increased susceptibility to apoptotic stimuli [19]. 
Omi/HtrA2 and neurodegeneration 
Recently, two single nucleotide polymorphisms in the Omi/HtrA2 gene that cause missense 
mutations (A141S and G399S) have been identified in relation to Parkinson’s disease [21].  In all 
cases, these mutations destroy/ severely impair the proteolytic activity of the enzyme.  Some 
studies have also implicated Omi/HtrA2 in the development of Alzheimer’s disease.  Originally, 
Omi/HtrA2 was identified as an interactor of Presenilin-1 in yeast two-hybrid screening [2].  
This was followed by another study which showed that the C-terminal portion of Presenilin-1 
can interact and enhance the proteolytic activity of Omi/HtrA2 [22]. More recent work has 
shown that Omi/HtrA2 is involved in the processing of APP [23] and can also interact with 
gamma-secretase [24], suggesting an important role in Alzheimer’s disease as well and possibly 
some other neurodegenerative disorders such as Huntington’s disease [25]. 
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Omi/HtrA2 in ischemia/reperfusion (I/R) injury 
Omi/HtrA2 shows ubiquitous expression in human tissues, and the proteolytic activity of the 
protein is significantly upregulated upon ischemia/reperfusion (I/R) injury.  Not so long ago, a 
specific inhibitor of Omi/HtrA2 namely ucf-101(5-[5-(2-nitrophenyl)furfuryl iodine]1,3-
diphenyl-2-thiobarbituric acid was characterized [26].  This inhibitor has been used successfully 
in I/R studies in different organs.  Using a mouse model of kidney I/R injury, it has been shown 
that inhibiting Omi/HtrA2 by use of ucf-101 or downregulating the protein by siRNA 
interference can confer significant protection to kidney cells from cisplatin or I/R mediated 
apoptosis [26-28].  Recent work has shown that HtrA2 gets translocated to the cytosol from the 
mitochondria where it promotes death of cardiomyocytes.  Use of ucf-101 results in decrease in 
myocardial apoptosis along with reduction in infarct size, recovery of mean arterial blood 
pressure and improvement in contractile dysfunction ([29-31].  Not only that, work by Althaus et 
al also has shown that inhibiting Omi/HtrA2 prior to brain ischemia in rats significantly reduced 
cellular damage and conferred neuroprotection [32].  
Omi/HtrA2 in cancer 
Besides Omi/HtrA2’s role in neurological disorders, a lot of recent work has identified potential 
involvement of the protein in tumor development as well.  Omi/HtrA2 has a cell-type specific 
varied expression levels in several tumors at different stages in comparison to normal tissues 
[33]. Omi/HtrA2 has been shown to be expressed in lower levels in endometrial and ovarian 
cancers [34], whereas shows higher expression in prostate cancer and many advanced gastric 
adenocarcinomas [34, 35]. Interestingly Omi/HtrA2 has also been shown to be involved in 
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anoikis; a form of apoptosis caused by the disruption of cell attachment and may be possibly 
helping in removing cancer cells [36].  
All these studies put together, seem to point to the fact that Omi/HtrA2 might have an important 
cell survival function depending on the subcellular localization.  One of the approaches used in 
the Zervos’ laboratory to study Omi/HtrA2 function is employing the Yeast Two-hybrid System 
to identify interacting partner proteins.  These interacting proteins could be new substrates of 
Omi/HtrA2 or modulators of its proteolytic activity.  In one such screen two new Omi/HtrA2 
interactors were isolated.  One of them is Hax-1 (HS-1 associated protein X-1), a mitochondrial 
anti-apoptotic protein that serves as a substrate for Omi/HtrA2 [37].  Hax-1 gets cleaved in the 
mitochondria before Omi/HtrA2 translocates to the cytoplasm suggesting that it precedes the 
cleavage of IAPs that takes place in the cytoplasm [37]. Our work identified a central role for 
Hax-1 and Omi/HtrA2 in regulation of apoptosis in mammalian cells [37]. 
The other interactor we isolated is called THAP5, whose function is yet to be characterized and 
which constitutes the topic of interest of my dissertation.  THAP5 belongs to the family of THAP 
proteins, which are a recently described evolutionarily conserved family of cellular factors [38].  
The following chapters of the dissertation will give a detailed characterization of this novel 
transcription factor which is believed to be important in various activities such as transcription 
repression, cell cycle arrest, and DNA damage response and also implicated in Coronary Artery 
Disease (CAD) and several tumors including melanoma. 
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CHAPTER 2: THAP5 IS A HUMAN CARDIAC SPECIFIC INHIBITOR OF 
CELL CYCLE THAT IS CLEAVED BY THE PRO-APOPTOTIC 
OMI/HTRA2 PROTEASE DURING CELL DEATH 
Introduction 
Omi/HtrA2 is a mitochondrial serine protease that has an essential role in both mitochondrial 
homeostasis as well as cell death [13].  Most of the studies on Omi/HtrA2 have substantially 
contributed to our understanding of the mechanism of its pro-apoptotic function.  On the contrary 
very little is known about its normal function within the mitochondria.  Upon induction of 
apoptosis, Omi/HtrA2 is released to the cytoplasm where it participates in caspase-dependent 
and caspase-independent cell death [4-8].  The mechanism of its pro-apoptotic activity involves 
degradation of specific substrates that includes mitochondrial protein HAX-1, cytoplasmic 
proteins XIAP, PEA/PED, and Apollon/Bruce [11, 12, 14, 37, 39] as well as, nuclear factors 
Grim-19, WARTS, and p73 [9, 16, 17, 40].   
The protease activity of Omi/HtrA2 is always necessary and essential for its pro-apoptotic 
function.  We have used the yeast two-hybrid system to isolate and characterize new Omi/HtrA2 
interacting proteins [26].  These interacting proteins could be new substrates of Omi/HtrA2 or 
modulators of its proteolytic activity.  Previous studies have shown that the proteolytic activity 
of Omi/HtrA2 can be regulated through specific protein-protein interactions mediated via its 
PDZ-domain [41].  In this report, we describe one such new Omi/HtrA2 interactor, the THAP5 
protein.  The THAP (Thanatos-Associated Protein) family of proteins comprises a group of 
nuclear factors defined by the presence of an approximately 90-residue protein motif (the THAP 
domain) [38].  THAP domains are atypical zinc fingers with specific zinc-dependent DNA 
binding activity and show similarity to the site-specific DNA-binding domain of the P element 
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transposase from Drosophila [38, 42].  THAP proteins are transcription factors and the limited 
information that exists on their function suggests that, they might be involved in gene regulation, 
cell cycle control, and/or apoptosis [43-45].  The figure below shows a schematic diagram of the 
human and drosophila THAP proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Schematic Diagram of Human and Drosophila THAP proteins 
THAP5 is the fifth member in the twelve-member family of human THAP proteins and is unique 
since outside its THAP domain, it shares no sequence homology to any other reported protein.  
THAP5 interacted with Omi/HtrA2 both in yeast and mammalian cells under pro-apoptotic 
conditions where Omi/HtrA2 is known to be released from mitochondria to the cytoplasm.  
Furthermore, THAP5 could be cleaved very efficiently in vitro by Omi/HtrA2 protease.  Since 
very little is known about the function of THAP5 we performed a detailed study to characterize 
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its normal function and the significance of its interaction and degradation by Omi/HtrA2.  We 
found THAP5 to be a tissue specific nuclear factor that is predominantly expressed in the human 
heart.  Interestingly, there is no mouse or rat orthologue of THAP5; this is a characteristic of 
some THAP-family members since it has also been reported for four other proteins, namely 
THAP6, THAP8, THAP9, and THAP10 [44, 46].  The figure below shows a diagram 
representing the THAP proteins including the human and Drosophila THAP proteins.  
The normal function of THAP5 is the regulation of cell cycle and ectopic expression of the 
protein caused cell cycle arrest.  During cell death, THAP5 was cleaved and removed by 
Omi/HtrA2 in cells treated with cisplatin and H2O2, but it was not affected in cells treated with 
etoposide and camptothecin.  Using the ucf-101 inhibitor of Omi/HtrA2, we could very 
effectively block THAP5 degradation and protect cells from undergoing apoptosis.  The 
degradation of THAP5 seen during experimentally induced cell death or cell injury is a 
physiological event that follows cellular damage and was observed in the myocardial infarction 
area (MI) of the heart tissues from patients with coronary artery disease (CAD). 
Materials and Methods 
Yeast Two-Hybrid Screen .  We used the yeast two-hybrid system to screen a HeLa as well as 
a melanocyte cDNA library as previously described [37].  The bait used was the mature, 
proteolytically active form of the Omi/HtrA2 protein (aa 134-458) cloned in the pGilda 
(Clontech) bait vector.  Several interacting proteins were identified in this screen.  One of these 
Omi/HtrA2 interactors isolated from the melanocyte cDNA library was a partial clone of a 
previously uncharacterized protein called THAP5.  The full-length cDNA for THAP5 encodes 
395 amino acids and was isolated from a Marathon Ready human heart cDNA library 
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(Clontech).  The specificity of THAP5 interaction with Omi/HtrA2 in yeast was tested using 
HtrA1, a mammalian homolog of Omi/HtrA2 that has 68% amino acid sequence similarity.  The 
presence and stability of the recombinant proteins in yeast cells was monitored by Western blot 
analysis using LexA-antibodies (for baits) or HA-antibodies (for preys).   
Interaction between Omi/HtrA2 and THAP5 in mammalian cells .  HEK293 cells were 
transfected in duplicates with either pEGFP-C1 empty vector (Clontech) or EGFP-THAP5 
plasmid using Lipofectamine 2000 reagent (Invitrogen).  EGFP-THAP5 encodes the full-length 
THAP5 protein fused in frame to EGFP-C1 vector.  Fourteen hours later, half of the cells were 
treated with cisplatin (50M) for 10 hours.  Cell lysates were prepared using RIPA buffer 
(150mM NaCl, 50mM Tris-HCl pH 7.5, 1% NP-40, 0.25% Na-DOC) containing the protease-
inhibitor cocktail (Roche).  Approximately 200g of total protein cell lysates were pre-cleared 
by mixing with protein G-Agarose beads (Roche) for 1 hour followed by incubation with the 
Omi/HtrA2 polyclonal antibody [37] for 2 hours at 4C.  Protein G-Agarose beads were then 
added and allowed to bind overnight at 4C.  Immunoprecipitates were collected by brief 
centrifugation, washed extensively with RIPA buffer, and resolved by SDS-PAGE.  They were 
then electro-transferred onto a PVDF membrane and probed with a mouse monoclonal GFP 
antibody (Santa Cruz Biotechnology) followed by a secondary goat anti-mouse HRP-conjugated 
antibody and the immunocomplex visualized by ECL (Pierce).  We also performed the reverse of 
this experiment by transfecting HEK293 cells with pEGFP-N1-Omi (1-458).  Approximately 
200g of total protein cell lysates were pre-cleared by mixing with protein G-Agarose beads 
(Roche) for 1 hour and then incubated with THAP5 polyclonal antibody, followed by Western 
blot using the GFP antibody as described above.   
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Northern blot analysis of THAP5 mRNA expression in human tissues .  A human 
mRNA tissue blot (Clontech) representing twelve human tissues was probed with a radiolabeled 
DNA probe corresponding to THAP5 protein sequence residues 163-395.  This DNA sequence is 
unique and has no homology to any other known gene in the GenBank.  The blot was hybridized 
with the radiolabeled probe at 42C, washed at 65C, and subjected to autoradiography [1].  To 
verify that equal amount of mRNA was present on each lane, the blot was stripped and re-probed 
for -actin mRNA expression.  
Degradation Assay.  The ability of His-Omi134-458 to cleave recombinant His-THAP5 protein 
in vitro was investigated.  The full-length cDNA for the THAP5 protein was cloned in frame in 
pET-28 vector (Novagen).  Bacterially expressed recombinant His-THAP5 was purified on 
nickel-nitrilotriacetic acid (NTA-agarose) affinity resin as described [37].  The synthesis and 
properties of the His-Omi134-458 has been previously reported [37].  His-Omi134-458 was incubated 
with His-THAP5 in 15L of reaction volume in assay buffer (20mM Na2HPO4 pH 8, 200mM 
NaCl and 5% glycerol).  In some of the reactions, the ucf-101 inhibitor was used.  After various 
incubation times at 37C the reactions were stopped through the addition of SDS-sample buffer.  
Reaction products were analyzed by SDS-PAGE followed by Coomassie blue staining.  
Cell Culture.  HEK293 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM), 
supplemented with 10% fetal calf serum (Hyclone), 2mM L-glutamine, 1.5g/L sodium 
bicarbonate, 1mM sodium pyruvate, 50 units/ml penicillin, 50g/ml streptomycin (Invitrogen).  
HeLa cells were grown in DMEM supplemented with 10% fetal calf serum, 2mM L-glutamine, 
50units/ml penicillin, 50g/ml streptomycin.  
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Sub-cellular localization of the THAP5 protein.   To investigate the sub-cellular 
localization of the THAP5 protein, the full-length cDNA (aa 1-395) was cloned in frame into 
EGFP-C1 vector (Clontech).  Furthermore, DNA sequence corresponding to amino acids 1-162 
or 163-395 of THAP5 protein were also amplified by PCR and cloned into EGFP-C1 vector.  
HeLa cells were grown on glass cover slips in 12-well plates.  Approximately 60% confluent 
cells were transiently transfected with 1g of the various GFP-constructs using Lipofectamine 
2000 Transfection Reagent (Invitrogen).  Twenty-four hours after transfection, cells were 
washed and fixed in 4% paraformaldehyde (PFA), permeabilized with 0.2% Triton X-100 and 
incubated with Texas red-phalloidin (Molecular Probes) to stain cytoplasm.  The cover slips 
were then washed and placed on microscope slides using Fluoromount-G as the mounting 
solution.  Slides were observed using a LSM510 confocal laser-scanning microscope (Zeiss).  
The expression and stability of the various GFP-fusion proteins was verified by Western blot 
analysis using GFP-specific antibodies (Santa Cruz Biotechnology). 
Expression, purification of His-tagged THAP5163-395 protein and antibody 
production.  PCR was used to amplify DNA sequence corresponding to a partial carboxyl 
terminus THAP5 (aa 163-395) polypeptide.  The PCR product was cloned in-frame in the 
bacterial expression vector pET-28 (Novagen).  For protein expression, BL21 (DE3) (Novagen) 
bacteria were transformed with pET-THAP5 and single colonies were grown overnight in LB 
medium containing Kanamycin.  The overnight culture (1ml) was used to inoculate 1L of LB 
medium and growth was continued at 37C until the OD600 was approximately 0.8.  At this time, 
2mM IPTG was added and the culture was placed in a shaking incubator for 4 hours at 25C.  
Bacteria were harvested by centrifugation and lysed in a buffer containing 6M Urea, 0.1M 
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NaH2PO4, 20mM Tris-HCl pH 8, and a protease inhibitor cocktail (Sigma).  The bacterial 
suspension was then sonicated and recombinant His-THAP5163-395 protein purified using Ni-NTA 
His-Bind Resin (Novagen).  The quality of the His-THAP5163-395 protein was monitored by SDS-
PAGE followed by Coomassie blue staining.  To make the polyclonal antibody, 15mg of purified 
human His-THAP5163-395 was used to immunize two rabbits.  Immunization, production, and 
purification of the polyclonal THAP5 antibody were performed by New England Peptide Inc.   
Western blot analysis of THAP5 protein expression in var ious human tissues.   
Since THAP5 is expressed only in human cells we used a commercially available Western blot 
that represents five human tissues (Calbiochem).  Each lane of the blot contains 10g of crude 
protein extract from the corresponding tissue.  We used our THAP5 polyclonal antibody at a 
1:5000 dilution.  The method and conditions for the Western blot analysis have been previously 
described [27, 37].  
Cell Cycle Analysis.   Human embryonic kidney cells (HEK293) were seeded onto six-well 
plates, synchronized with serum starvation [47, 48], and then transiently transfected with EGFP-
C1 empty vector (Clontech) or EGFP-THAP5 using Lipofectamine 2000 Transfection Reagent 
(Invitrogen).  Forty or fifty hours after transfection, cells were washed and fixed in 4% 
paraformaldehyde (PFA).  The cells were then washed, permeabilized with 0.1% Saponin and 
stained with 7-amino-actinomycin D (7-AAD) (5L per 100L of PBS) and incubated for 30 
minutes at 37C.  GFP positive cells in the transfected population were measured using a 
FACSCalibur Flow Cytometer (BD Biosciences) [49]  and analyzed using ModFitLT software.  
Cell Death Assays.   HeLa cells were treated for 12 hours with different chemicals: 
camptothecin (100M), cisplatin (5M), etoposide (20M), H2O2 (0.2mM) and Staurosporine 
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(100M).  HeLa cells were grown in six-well plates in the appropriate medium until they 
reached 70-80% confluency; they were then treated with ucf-101 (20 or 30M) for 20 minutes 
followed by cisplatin (5M) or H2O2 (0.2mM) treatment for 12 hours.  Cells were detached with 
1X Trypsin-EDTA (Gibco), washed twice with ice-cold PBS, half of them were used for 
Western Blot analysis and the rest for apoptotic assay.  Western Blot analysis was performed as 
described [27, 37].  The apoptotic assay was performed according to BD Biosciences protocol.  
Briefly, cells were suspended in 1X binding buffer and stained with Annexin V (apoptotic cell) 
and 7-AAD (necrotic cells) [50-52].  Samples were analyzed on a FACSCalibur Flow Cytometer 
(BD Biosciences).  
Expression of THAP5 in the heart of patients with coronary artery disease (CAD).   
Human cardiac tissues were prepared as described [53].  Briefly, human cardiac tissue samples 
were taken from the left ventricles of failing human hearts that were explanted in the course of 
heart transplantation.  The study's protocol was approved by the local ethics committee, and 
written informed consent given by patients, according to the National Disease Research 
Interchange (NDRI).  Hearts from patients with end-stage heart failure who were undergoing 
cardiac transplantation because of either DCM (Dilated Cardiomyopathy) or CAD (Coronary 
Artery Disease) were investigated.  Furthermore, healthy donor (HD) hearts that were ultimately 
rejected for transplantation because of technical reasons were also included in this study as 
healthy tissue control.  For Western blot analysis, 100 mg of tissue was ground in liquid nitrogen 
and homogenized with an Ultra-Turrax T8 (IKA-werke) in ice-cold lysis buffer containing 
150mM NaCl, 20mM Tris-HCl pH 7.6, 1mM CaCl2, 1mM MgCl2, 10% Glycerol, 1% NP40 and 
protease and phosphatase inhibitors cocktail (Roche).  Homogenate was cleared by 
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centrifugation for 10 min at 14,000 g. Protein concentrations were determined using the Bio-Rad 
protein assay (Bio-Rad).  Approximately 20g of whole cell extract was resuspended in SDS-
sample buffer and boiled for 3 minutes.  Samples were resolved by SDS-PAGE and electro-
transferred onto PVDF membranes (Pall Life Sciences) using a Semi-Dry cell Transfer Blot 
(Bio-Rad).  4% nonfat dry milk in TBST buffer was used to block any non-specific binding.  The 
membrane was incubated with our THAP5 polyclonal antibody (1:5000) followed by a 
secondary HRP-conjugated goat anti-rabbit (Jackson ImmunoResearch) (1:15000) and 
visualization by ECL (Pierce).   
Statistical analysis.   All quantitative data are expressed as mean ±SD. Differences among 
groups were analyzed by one-way analysis of variance (ANOVA) followed by Tukey’s Post-hoc 
test.  A value of P<0.05 was considered significant.  
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Results 
Isolation of THAP5 as an Omi/HtrA2 interactor.  We used the yeast two-hybrid 
system to isolate Omi/HtrA2 interactors.  We screened two different cDNA libraries derived 
from HeLa cells and primary human melanocytes.  We used two different cDNA libraries in 
order to screen as many diverse proteins as possible, including any potential tissue specific 
interactors of Omi/HtrA2.  Furthermore, one of the cDNA libraries was prepared from primary 
cells to avoid a potential problem often seen in cDNA libraries prepared from transformed cell 
lines.  Cells lines such as HeLa used here often have deregulated expression of genes involved in 
cell growth as well as under-representation of pro-apoptotic cDNAs.  The bait in this screen was 
the LexA-Omi134-458 that represents the mature active form of the Omi/HtrA2 enzyme [37].  The 
screen was performed as described and several novel Omi/HtrA2 interacting proteins were 
identified [37].  One of the specific interactors from the human melanocyte cDNA library was a 
partial polypeptide of THAP5.  THAP5 is the fifth member of a recently described twelve-
member family of proteins characterized by the presence of a THAP (Thanatos-Greek for death) 
motif at the amino terminus of the protein [38].  Using specific primers and RACE we were able 
to isolate the full-length cDNA, which was then cloned back into the pGJ4-5 vector and its 
interaction with Omi/HtrA2 monitored.  Figure 3A shows that full-length THAP5 interacts 
strongly with the Omi/HtrA2.  Furthermore, the specificity of the interaction was tested using 
HtrA1, a human homologue of Omi/HtrA2 that has 68% amino acid sequence similarity.  No 
interaction was observed in this yeast two-hybrid assay between these two proteins (Fig. 3A).  
The expression and stability of the different baits and preys was monitored and verified by 
Western blot analysis (results not shown).  
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Interaction of Omi/HtrA2 with THAP5 in mammalian cells during apoptosis.   To 
investigate whether Omi/HtrA2 can interact with THAP5 in vivo, HEK293 cells were transfected 
with a construct encoding GFP-THAP5.  Cells were treated with cisplatin for 12 hours to induce 
apoptosis.  After this time, Omi/HtrA2 antibodies were used to precipitate endogenous 
Omi/HtrA2 protein and the presence of any GFP-THAP5 protein in the complex was monitored 
by Western blot analysis using a GFP-specific monoclonal antibody (Santa Cruz Biotechnology).  
Figure 3B shows that endogenous Omi/HtrA2 interacts with GFP-THAP5 in HEK293 only in 
cells treated with cisplatin and undergoing apoptosis.  No interaction between Omi/HtrA2 and 
GFP-THAP5 was observed under normal non-apoptotic conditions.  We also performed the 
reverse experiment by transfecting HEK293 cells with GFP-Omi and using the THAP5 antibody 
to precipitate endogenous protein and any GFP-Omi associated with it.  This experiment also 
clearly shows that THAP5 and GFP-Omi can associate in mammalian cells but only during 
apoptotic conditions (Fig. 3C) 
THAP5 is cleaved by Omi/HtrA2 protease in vitro.  To test the ability of Omi/HtrA2 
protease to cleave the THAP5 protein in vitro, bacterially made His-THAP5 was incubated with 
His-Omi/HtrA2134-458 protease for different time periods.  Figure 3D shows that His-
Omi/HtrA2134-458 was able to degrade the THAP5 protein in this assay.  To verify that cleavage 
of THAP5 was due to Omi/HtrA2 activity and not by some other contaminated bacterial protease 
we used its specific inhibitor ucf-101 [26].  When used in this assay, ucf-101 was able to prevent 
the degradation of THAP5 by Omi/HtrA2 (Fig.3D). 
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Expression of THAP5: mRNA and protein.  Figure 4A is a schematic diagram of the 
THAP5 protein.  The nucleotide sequence predicts a protein consisting of 395 amino acids.  The 
THAP domain is located at its amino terminus and shows high homology to the other eleven 
members of the human THAP family of proteins.  Outside the THAP domain, THAP5 protein 
has no similarity to any other known protein sequence that is uploaded in the GenBank.  A 
coiled-coil region is also predicted at its carboxyl-terminus.  Since there is no mouse or rat 
orthologs for THAP5, a human Northern blot representing various tissues was used to investigate 
THAP5 mRNA expression.  THAP5 expression is represented by a specific mRNA band of 
approximately 3.2kb (Fig. 4B).  THAP5 mRNA shows very high expression in the human heart 
and when the blot is overexposed, some expression is also seen in the human brain and skeletal 
muscle (Fig. 4B).  No expression of THAP5 is detected in any of the other human tissues 
represented on this blot.  To verify that there is a bona-fide THAP5 protein present in these 
human tissues we raised a polyclonal antibody against a recombinant His-THAP5163-395.  This 
antibody was used on a Western blot containing extracts from various human tissues 
(Calbiochem).  Figure 4C shows that a 50kDa polypeptide is readily detectable in human heart, 
brain, and skeletal muscle.  A higher molecular weight band is also detected in the human brain 
that corresponds to a phosphorylated form of the same THAP5 protein (unpublished data).  The 
relative levels of the THAP5 protein versus mRNA in the three human tissues do not correspond 
and this is probably due to the poor quality (protein degradation) of the commercially available 
human Western blot.  
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Sub-cellular localization of the THAP5 protein.  The cDNA sequence corresponding to 
the full-length THAP5 protein was cloned into the GFPC1 vector.  The GFP-THAP5 vector was 
transfected into HeLa cells and 24 hours later the sub-cellular localization of the protein was 
observed using a confocal microscope as previously described  [27].  Figure 5A shows that, the 
full-length GFP-THAP5 protein is localized exclusively in the cell nucleus but is excluded from 
the nucleoli.  There are two discernible domains in the THAP5 protein: (a) the THAP domain 
(90aa) present at the amino terminus that shares homology with the corresponding domain in the 
other eleven members of the THAP family of proteins and (b) the rest of the THAP5 protein (91-
395aa) that shows no homology to any other known protein sequence in the data banks.  
Therefore, we cloned DNA sequence corresponding to the amino terminus of the protein 
including the THAP domain or the unique carboxyl-terminus of THAP5 into the GFP vector in 
order to investigate their potential role targeting the protein to the nucleus.  Figure 5B shows that 
the THAP5 protein that lacks the amino terminus is now predominantly cytoplasmic, whereas the 
THAP domain alone localizes exclusively in the cell nucleus (Fig. 5C).  Figure 5D is a Western 
blot to verify the expression and stability of the three different GFP fusion proteins used in this 
experiment.   
THAP5 is a potential regulator of cell cycle.   Previous reports suggested that some 
members of the THAP-family of proteins could inhibit cell cycle progression [43].  Therefore, 
we investigated whether ectopic expression of a GFP-THAP5 protein in human embryonic 
kidney (HEK293) will interfere with the cell cycle progression.  Cells were synchronized and 
transfected with GFP-THAP5 or the empty GFP vector and 40 or 50 hours later the percentage of 
transfected cells at various points of the cell cycle were estimated.  Figure 6 shows an 
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accumulation of GFP-THAP5 expressing cells at the G2/M phase compared to cells expressing 
GFP alone forty hours post transfection.  This difference becomes more pronounced after fifty 
hours where over 28% of the GFP-THAP5 expressing cells were found in the G2/M phase versus 
2% of cells transfected with GFP vector.  
THAP5 is degraded in cells treated with cisplatin or H2O2.   In order to investigate 
whether THAP5 protein is regulated during apoptosis, HeLa cells were treated with various 
chemicals known to induce apoptosis including: camptothecin, cisplatin, etoposide, H2O2 and 
staurosporine, subsequently cell death was measured using Annexin V staining and Flow 
Cytometry [37].  THAP5 protein level was monitored by Western blot analysis of cell extracts 
and it was significantly reduced in cells treated with cisplatin or H2O2 (Fig. 7).  These chemicals 
also induced the maximum cell death (64% and 58% respectively) in this assay.  In cells treated 
with cisplatin the phosphorylated form of THAP5 (upper band on the blot) was preferentially 
cleaved whereas in cells treated with H2O2 both forms of the protein were equally degraded.   
Ucf-101 inhibitor prevents THAP5 degradation.   We investigated whether the 
Omi/HtrA2 protease is responsible for the degradation of THAP5 observed in HeLa cells during 
apoptosis.  For this, HeLa cells were treated with cisplatin and the percentage of cell death 
monitored by Annexin V staining and Flow Cytometry and the levels of THAP5 protein 
monitored by Western blot analysis.  HeLa cells treated with 5M cisplatin for 12 hours resulted 
in 42% cell death of the population (Fig. 8).  The cell death in these cells coincided with a 
dramatic reduction in the level of THAP5 protein.  We also performed the same experiment in 
the presence of two different concentrations of ucf-101, a specific inhibitor of the proteolytic 
activity of Omi/HtrA2 [26].  In this case, the percentage of apoptotic cells in the population was 
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reduced to 21%.  The ucf-101 inhibitor was also able to protect the degradation of the THAP5 
protein implicating Omi/HtrA2 protease in this process. 
Expression of THAP5 protein in heart tissues derived from patients with 
coronary artery disease.  THAP5 expression is highest in the human heart suggesting a 
potential role of this protein in the normal function of the cardiomyocytes.  We monitored the 
protein level of THAP5 in the heart of patients with various heart diseases including Coronary 
Artery Disease (CAD) and Dilated Cardiomyopathy (DCM).  Figure 9A shows the expression of 
THAP5 protein in the remote zone (CAD-RZ), border zone (CAD-BZ), and myocardial 
infarction area (CAD-MI) in hearts of three CAD patients.  In two of the patients, there is clear 
reduction in the level of THAP5 in the CAD-MI area compared to the CAD-RZ and CAD-BZ.  
The myocardial infarction area is the part of the heart that sustains maximum injury in CAD.  
Therefore, this area is expected to contain most damaged and apoptotic cells.  Figure 9B shows 
the expression of THAP5 protein in the heart tissue of three patients with dilated cardiomyopathy 
(DCM) and three healthy donors (HD).  No significant difference is seen in the level of THAP5 
protein in the hearts of DCM patients or healthy donors.  The blot was also probed with 
GAPDH-specific antibody to verify that equal amount of protein extract was used in each lane. 
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Discussion 
Omi/HtrA2 is a nuclear encoded mitochondrial protease that has homology to bacterial HtrA 
chaperones [1, 54, 55].  Recent evidence suggests that Omi/HtrA2 has two distinct functions 
both requiring its protease activity.  Omi/HtrA2 can be a pro-apoptotic protein as well as a pro-
survival factor depending on its sub-cellular location.  The pro-survival function of Omi/HtrA2 
was based on studies on motor neuron degeneration 2 (mnd2) mice that carry a single mutation 
affecting the proteolytic activity of Omi/HtrA2 [20].  Mnd2 homozygous animals suffer muscle 
wasting, neurodegeneration, and die by six weeks of age.  Based on these studies, it is assumed 
that the primary function (physiological function) of Omi/HtrA2 in mammalian cells is to 
somehow maintain mitochondrial homeostasis necessary for cell survival [19, 20].  The other 
function of Omi/HtrA2 (pathological function) becomes operational only under conditions 
leading to cell death where Omi/HtrA2 is released to the cytoplasm as a pro-apoptotic protein 
and participates in caspase-dependent as well as caspase-independent apoptosis [4, 5, 8].   
Most of the studies reported so far have provided significant new information on the mechanism 
of Omi/HtrA2’s pro-apoptotic function but little if nothing on its pro-survival function is known.  
Omi/HtrA2, when released to the cytoplasm, binds and degrades several substrates including 
IAPs, PEA/PED, and Apollon/Bruce [11, 12, 14, 39].  Some of these proteins are clearly anti-
apoptotic factors and their removal by Omi/HtrA2 can undoubtedly accelerate cell death.  Others 
have a more obscure function and their association and cleavage by Omi/HtrA2, in the context of 
inducing cell death, is more difficult to explain.  In the present study, we report the 
characterization of THAP5, the fifth member of the THAP family of proteins as a specific 
interactor and substrate of Omi/HtrA2 protease.  THAP proteins comprise a recently described 
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family of cellular factors with unique structural and functional characteristics.  They are defined 
by the presence of the THAP domain, an atypical zinc-dependent DNA-binding domain of 
approximately 90 amino acids.   
There are 113 THAP proteins listed in the databases and in humans, there are 12 distinct proteins 
(THAP0-THAP11) [38].  All 12 human THAP proteins have a single THAP domain at their 
amino terminus.  In Drosophila there are seven THAP proteins two of which contain more than 
one THAP domain, CG14860 has two THAP domains and the CG10631 is predicted to have as 
many as 27 THAP domains [38].  THAP domains are unique as DNA binding motifs due to a 
significant similarity with the DNA binding domain of Drosophila P element transposase.  This 
similarity includes the size of the THAP domain, its location in the protein and the conservation 
in the number and residues that define the domain [38].  THAP0, also known as the death-
associated protein DAP4/p52rIPK, was identified as one of the genes induced by IFN--induced 
apoptosis and in an independent study as an interactor of PKR protein kinase [56, 57].  THAP1 
was originally defined as a pro-apoptotic nuclear factor localized at the promyelocytic leukemia 
nuclear bodies (PML NBs) and interacting with prostate-apoptosis-response-4 (Par-4) protein 
[45].   
Since very little is known about THAP5 we embarked on a detailed study beginning with its 
expression.  In human tissues THAP5 mRNA is predominantly expressed in the human heart 
although low expression is also detected in skeletal muscle and brain.  More significantly, we 
found no orthologs for THAP5 in mouse (Mus musculus) or rat (Rattus norvegicus).  The closest 
orthologs were detected in Macaca fascicularis, Bos taurus, and Gallus gallus.  The absence of 
orthologs in mouse and rat has also been reported for four other members of the THAP family, 
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the THAP6, THAP8, THAP9, and THAP10 proteins [46].  It was suggested that some THAP 
genes might have originated from a domestication event of a single copy of P element 
transposase that took place in the human lineage after it had diverged from the rodent lineage 
[42].  Alternatively, THAP gene domestication might have occurred earlier in the evolution but 
was later lost in the lineage leading to rodents [42]. 
To verify that THAP5 is a bona fide human protein, we raised a polyclonal antibody against the 
unique part of the protein (aa163-395) that does not include the THAP domain.  This polyclonal 
antibody clearly recognized a specific band of 50 kDa, corresponding to THAP5 in human heart, 
skeletal muscle, and brain.  In human brain a 52kDa polypeptide was also detected that could 
possibly correspond to a phosphorylated form of the same THAP5 protein.  The THAP5 
antibody did not detect any specific protein bands when tested against various mouse or rat tissue 
extracts (results not shown).  
To investigate the sub-cellular localization of THAP5, we expressed the full-length protein fused 
to GFP in HeLa cells.  The fusion protein, GFP-THAP5, shows exclusive nuclear localization 
but is excluded from the nucleoli.  The amino terminus of the protein that includes the THAP5 
domain is responsible for its nuclear localization.  This is the part of the protein implicated in 
DNA binding as well as protein-protein interactions [58].  The interaction with Omi/HtrA2 is 
mediated by the carboxyl-terminus of THAP5 that binds the PDZ-domain of Omi/HtrA2.  The 
carboxyl-terminus of THAP5 has the amino acid sequence EVTMI* that conforms to the 
consensus sequence for PDZ (Omi) binding proteins [41, 59]. 
Previous studies have shown two members of the same family, THAP1 and THAP11 can 
regulate cell proliferation [43, 60].  Furthermore, genetic studies using C. elegans support a role 
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of THAP proteins in cell cycle regulation.  These studies demonstrated a genetic interaction 
between LIN-35/Rb, which is the C. elegans retinoblastoma homologue and four C. elegans 
THAP proteins, LIN-36, LIN-15B, LIN-15A, and HIM-17.  LIN-36 and LIN-15B are known 
inhibitors of G1/S cell cycle transition [44, 61-65].  Also, in zebrafish the ortholog of the cell 
cycle transcription factor E2F6 has a THAP domain and functions as a repressor of E2-F-
dependent transcription during S phase [66].  Based on these reports we decided to investigate if 
THAP5 plays any role in the regulation of cell cycle. 
For these studies, we ectopically expressed GFP-THAP5 in a human embryonic kidney 
(HEK293).  This cell line expresses endogenous THAP5 protein and can be transfected with high 
efficiency.  The results from these experiments clearly show, GFP-THAP5 had a dramatic effect 
blocking the progression of transfected cells through the cell cycle progression and causing high 
accumulation of cells at the G2/M phase.  The mechanism by which THAP5 inhibits cell cycle is 
not known and it most likely will involve the direct regulation of cell cycle genes.  THAP5 has 
an atypical zinc finger domain at its amino terminus that can bind to specific DNA sequences on 
different promoters.  A recent study showed that another member of the same family, THAP11, 
could inhibit cell cycle by binding to the promoter of c-Myc and down-regulating its expression 
[60]. 
To investigate the role of the THAP5-Omi/HtrA2 interaction during apoptosis, HeLa cells that 
normally express THAP5 were treated with various chemicals to induce cell death.  Under these 
conditions, Omi/HtrA2 is released from mitochondria and becomes a pro-apoptotic protein.  In 
these experiments, the THAP5 protein was cleaved in cells treated with cisplatin or H2O2 and the 
degree of THAP5 degradation increased proportionally with the rate of apoptosis in the cell 
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population.  No significant cleavage of THAP5 was seen in cells treated with Etoposide and 
Camptothecin but these chemicals also caused minimal cell death in this protocol and cell line 
used for these experiments.  We used a specific inhibitor to show that Omi/HtrA2 is responsible 
for THAP5 degradation.  This inhibitor, ucf-101, was developed in our laboratory and has been 
extensively studied in various systems of cell death [26, 31, 37].  When the ucf-101 inhibitor was 
used, it clearly blocked THAP5 cleavage and protected cells from apoptosis.  
THAP5 is hyper-expressed in the human heart but there are no rodent orthologs, therefore 
limiting the type of studies that can be done to investigate its potential involvement in the 
development or progression of heart disease.  We obtained small tissue samples from patients 
with several human heart diseases including coronary artery disease (CAD) and dilated 
cardiomyopathy (DCM).  In CAD patients, we were able to detect a decrease in the THAP5 
protein level in the myocardial infarction (MI) area when compared to remote zone (RZ) or 
border zone (BZ) areas of the same heart.  These results, though preliminary, suggest that during 
pathological conditions resulting in myocardial cell death, such as MI, the THAP5 protein 
decreases significantly in areas of the heart that sustained maximum cell damage.  There was no 
difference in THAP5 protein levels in DCM patients compared to normal (donor) heart.  
Previous studies have shown that Omi/HtrA2 is a key player in myocardial ischemia/reperfusion 
injury [29].  Furthermore, inhibition of the proteolytic activity of Omi/HtrA2 using the ucf-101 
inhibitor improved post-ischemic myocardial function and reduction of the myocardial infarct 
size [29-31].   
THAP5 is the first human, heart-specific substrate of Omi/HtrA2 identified thus far.  Under 
normal, physiological conditions THAP5 functions as an inhibitor of cell cycle.  This dual 
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function of THAP5 supports previous studies that have shown the existence of a cross talk 
between cell cycle control and apoptosis in cardiomyocytes.  For example, over-expression of 
the cell cycle inhibitor p57
kip2 
in cardiomyocytes was shown to attenuate ischemia-reperfusion 
injury in the mouse heart [67].  In another study, cyclin A/cdk2 activation was involved in 
hypoxia-induced apoptosis in cardiomyocytes [68].  The hyper-expression of THAP5 in human 
heart and its regulation during cell death by Omi/HtrA2 suggests this pathway plays a significant 
in the normal function of the heart.  Furthermore, THAP5 might be involved in the development 
and progression of heart disease especially in coronary artery disease.   
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Figure 3: THAP5 is an interactor and substrate of Omi/HtrA2 protease.  
A, Yeast colonies were transformed with plasmids encoding the indicated baits and full length THAP5 
cloned into the prey vector.  The specificity of THAP5 and Omi/HtrA2 interaction was verified using a 
closely related homologue, the HtrA1 protein.  Blue color results from a positive protein-protein 
interaction.  B, HEK293 cells were transfected with EGFP, EGFP-THAP5 or GFP-Omi.  Twelve hours 
after transfection one plate was treated with Cisplatin to induce apoptosis and one plate was used as 
control.  A polyclonal Omi/HtrA2 antibody was used for immunoprecipitation. The immunoprecipitated 
complex was resolved on SDS-PAGE, transferred and the presence of GFP-THAP5 fusion protein 
detected using a specific anti-GFP antibody.  Lane 1 shows crude lysates of GFP-THAP5 transfected 
cells.  Lane 2 shows Co-IP lysates obtained from cells transfected with GFP empty vector.  Lane 3 shows 
Co-IP lysates obtained from cells transfected with GFP-THAP5 control cells and lane 4 shows Co-IP 
lysates obtained from cells transfected GFP-THAP5 and then treated with cisplatin.  C, Shows the reverse 
experiment described in Fig 1B.  HEK293 cells were transfected with GFP-Omi and THAP5 antiserum 
was used in the Co-IP and anti-GFP on the Western blot to detect the GFP-Omi.  Lane 1 shows total cell 
lysates of GFP-Omi transfected cells.  Lane 2 shows Co-IP lysates obtained from cells transfected with 
GFP empty vector.  Lane 3 shows Co-IP lysates obtained from cells transfected with GFP-Omi control 
cells and lane 4 shows Co-IP lysates obtained from cells transfected GFP-Omi and then treated with 
cisplatin.  In both Figures 1B and 1C THAP5 was co-precipitated with Omi/HtrA2 but only in cells where 
apoptosis was induced.  D, Purified His-THAP5 was incubated with His-Omi134-458 at 37°C for the 
indicated time periods.  For some assays, Omi/HtrA2 was pre-incubated with ucf-101 inhibitor 10 min 
prior to addition of His-THAP5.  The reactions were resolved on SDS-PAGE and the gel stained with 
Coomassie Blue.  Lane 1, His-THAP5 control (400ng); lane 2, His- Omi134-458 control (400ng), lanes 3, 5, 
7 and 9, His-Omi+His-THAP5 at different time points; lane 4, 6, 8, and 10, His-Omi + His-THAP5+ ucf-
101 (50M); lane 11, His-THAP5 + ucf-101 control 
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Figure 4.  Expression of THAP5: mRNA and protein in human tissues. 
A,   Schematic representation of the THAP5 protein encoded by 395 amino acids.  The light gray box 
represents the 90aa THAP domain, which is characteristic of all THAP proteins.  B, Northern blot 
analysis of THAP5 expression in human tissues.  A commercially available Northern blot (Clontech) 
containing 2g/lane poly (A) mRNA from various adult human tissues was probed with 32P-THAP5 (539-
1342) cDNA.  A single transcript was detected of about 3.2 kb.  The blot clearly shows high expression of 
THAP5 in the human heart, some expression was also seen in skeletal muscle and brain.  -actin probe 
was used to verify that equal amounts of mRNA were present in each lane.  C, Western blot analysis of 
THAP5 protein in multiple human tissue; A commercial western blot  (INSTA-blot Calbiochem) 
containing 15g/lane of total protein from adult human tissues was incubated with rabbit-polyclonal anti-
THAP5 antibody followed by a secondary antibody, HRP-conjugated goat anti-rabbit and 
chemiluminescence detection. 
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Figure 5.  Sub-cellular localization of the THAP5 protein in mammalian cells.                     
A,   Confocal image of HeLa cells transfected with GFP-THAP51-395 shows exclusive nuclear localization 
(green in panel A”).  B,   HeLa cells transfected with GFP-THAP5163-395 show cytoplasmic localization 
(green in panel B”).  C,  HeLa cells transfected with GFP-THAP51-162 show exclusive nuclear localization 
(green in panel C”) of this protein.  The cells were also stained with Texas red-phalloidin (Molecular 
Probes) that stain actin filaments (red).  Nomarski/DIC images of the same cells are shown in panel A’, 
B’ and C’ respectively.  D, The stability of EGFP-fusion proteins was monitored by Western blot analysis 
using an anti-GFP antibody.  Equal amounts of whole-cell lysates, obtained 24 hrs post-transfection were 
subjected to SDS-PAGE followed by Western blot analysis using anti-GFP monoclonal antibody as 
described in Materials and Methods.  Lane 1, lane 2 and 3 represent lysates obtained after transfection of 
HeLa cells with GFP- THAP51-395, GFP-THAP5163-395, and GFP- THAP51-162 respectively. 
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Figure 6.  Over-expression of GFP-THAP5 causes accumulation of cells in G2/M phase.   
HEK293 cells were transiently transfected with GFP vector alone or GFP-THAP5.  40hrs and 50hrs post 
transfection cells were stained with 7-AAD and the DNA content was analyzed using ModFitLT 
software.  Panel C represents the percentages of GFP positive cells at different phases of cell cycle 40 hrs 
after transfection and panel F represents 50hrs.  A, Histogram results from representative experiments in 
cells transfected with GFP vector at 40 and D, 50 hours.  B, Cells transfected with GFP-THAP5 40 and E, 
50 hours show significant increase in the percentage of cells in G2/M phase.  Data are means SD of four 
independent experiments. 
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Figure 7.  THAP5 protein level is regulated during apoptosis.  
Total cell lysates were prepared from HeLa cells after induction of apoptosis using different chemicals 
(Camptothecin, Cisplatin, Etoposide, H2O2 and Staurosporine).  A, Cell death was monitored in the 
treated cell populations by Annexin V and 7-AAD staining and analyzed by Flow cytometry.  B, Cells 
extract were prepared followed by Western blot analysis of the same samples.  Lane 1 shows lysates from 
control, untreated cells, lanes 2, 3, 4 show cell extracts from HeLa treated with the chemical indicated 
above.  actin antibody was used to verify that equal amounts of protein were present in each lane.  
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Figure 8.  A specific inhibitor of Omi/HtrA2 blocks THAP5 cleavage and protects HeLa 
cells from apoptosis.  
A, HeLa cells were treated with 20 or 30M of ucf-101 and apoptosis was induced with 5M cisplatin for 
12 hours.  Apoptosis was monitored using Annexin V and 7-AAD staining and analyzed by Flow 
cytometry.  B, Extracts were prepared from the same cell population and analyzed by SDS-PAGE and 
Western blot analysis using THAP5 antibody.  Cisplatin treatment caused a dramatic reduction in THAP5 
protein level (lane 2).  This corresponds with increased apoptosis in the cell population.  When HeLa cells 
were treated with ucf-101 followed by cisplatin, the inhibitor substantially protected THAP5 proteins and 
the percentage of apoptotic cells was significantly reduced (lanes 3 and 4).  actin antibody was used to 
verify that equal amounts of protein were present in each lane. 
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Figure 9.  THAP5 protein levels in heart tissues from patients with coronary artery disease 
(CAD).   
A, Heart tissue extracts from three patients with coronary artery disease (CAD) were used in a Western 
blot to monitor the expression of THAP5 protein.  Extracts were prepared from three areas on each heart 
corresponding to the remote zone (CAD-RZ), border zone (CAD-BZ), and the infarction (CAD-MI) area.  
B, Human heart tissue lysates from three healthy donors (HD 1 to 3) and three DCM patients (DCM 1 to 
3) were probed for THAP5 expression. 
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CHAPTER 3: THAP5 IS A DNA BINDING PROTEIN AND A 
TRANSCRIPTIONAL REPRESSOR WITH A ROLE IN MELANOMA 
CELL DEATH 
Introduction 
THAP proteins are zinc dependent DNA binding proteins involved in several functions such as 
cell proliferation, apoptosis, cell cycle, chromosome segregation, chromatin modification and 
transcriptional regulation [38]. THAP stands for Thanatos Associated Protein (derived from 
Thanatos which means death in Greek) [38]. These proteins are defined by the presence of an 
approximately 90 amino acid THAP domain at their amino terminus.  THAP domains are 
evolutionarily conserved motifs with specific amino acid residues that are necessary for the DNA 
binding activity of the THAP proteins [38, 42, 44].   Twelve human THAP proteins (THAP0-11) 
have been identified but most of the studies have been focused on THAP0 (DAP4), THAP1, 
THAP7 and THAP11 [43, 44, 56-58, 60]. Very little, if anything, is known about the function of 
the other members of the THAP family proteins.  
The first THAP protein to be studied was THAP0/ DAP4 (death associated protein-4) [56, 57]. 
THAP0 has been shown to enhance apoptosis caused by the overexpression of MST-1 protein 
[69].  THAP1 has been shown to be a nuclear protein associated with promyelocytic leukemia 
nuclear bodies and TNF- induced apoptosis [45]. It can also act as a regulator of cell cycle 
(G1/S phase) by regulating the expression of the RRM11 gene, a pRb/E2F target protein [43].  
THAP7 is a chromatin associated transcriptional repressor protein that recruits histone 
deacetylase 3 (HDAC3) and nuclear hormone receptor corepressors (NCoR) [58, 70]. THAP11 
has been shown to suppress cell growth by transcriptional downregulation of c-Myc [60].   The 
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mouse homolog of THAP11, called Ronin, was identified as an essential factor for 
embryogenesis and embryonic stem (ES) cell pluripotency [71].  
In our previous work, we identified the THAP5 protein as an interactor and substrate of the 
mitochondrial serine protease Omi/HtrA2 [72] (The Am Physiol Soc, used with permission). 
THAP5 is a nuclear protein with a restricted pattern of expression and is present predominantly 
in the human heart.  Furthermore, there is no mouse or rat homolog for THAP5.  The closest 
orthologs have been detected in monkey, cow and chicken.  The absence of mouse/rat homolog 
has also been noted in some other THAP proteins, namely THAP6, THAP8, THAP9 and 
THAP10 [46].  Our studies showed that THAP5 is an inhibitor of cell cycle and is cleaved by the 
pro-apoptotic protease Omi/HtrA2 during cell death [72]. The levels of THAP5 protein are 
significantly reduced in the myocardial infarction area of human heart tissues obtained from 
patients suffering from coronary artery disease (CAD) suggesting a potential role of this protein 
in the development and/or progression of human heart disease [72].  
In this work, we extend our studies on the mechanism of the normal function of THAP5 and its 
potential role in cell death.  For this, we used human melanoma cells since THAP5 was 
originally isolated from a human melanocyte cDNA library [72].  In addition, although THAP5 
is mostly expressed in human heart, human heart tissues are hard to obtain and there is no human 
heart cell line.  Nothing is known about the biological role of THAP5 in melanocytes and 
melanoma cells.  We found, upon UV or cisplatin treatment of melanoma cells, THAP5 protein 
is induced considerably.  The induction of THAP5 mirrors the degree of apoptotic cell death in 
the melanoma population.  Overexpression of THAP5 sensitizes melanoma cells to UV-induced 
apoptosis.  To further investigate the mechanism of THAP5 function we used an in vitro binding 
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selection and identified an 11-nucleotide consensus DNA-binding sequence specifically 
recognized by THAP5 protein.  In addition to its DNA binding ability, THAP5 was able to 
repress the transcription of a reporter gene in a heterologous system.  In summary, our work 
defines THAP5 as a DNA binding protein that can potentially repress the transcription of target 
genes involved in UV or cisplatin-induced damage and cell death of melanoma cells. 
Materials and methods 
Cell culture.  Melanoma (MEL-2, MEL-18, MMG1, SMYM, 397mel, 624mel, 888mel, 
928mel, SKmel23, RPM-ML, PM-WK, and MM-LH), stomach cancer (MNK7 and MNK28), 
lung cancer (A549), Ovarian Cancer (ES2), normal monkey kidney (cos7) cell lines were grown 
in Life Technologies RPMI 1640 medium (Invitrogen, Carlsbad, CA) supplemented with 10% 
heat-inactivated fetal bovine serum (FBS).  All cell lines were cultured at 37 ˚C in a humidified 
atmosphere containing 5% CO2, as previously described [73]. HEK-293 cells were grown in 
Dulbecco's modified Eagle's medium (DMEM),  supplemented with 10% fetal calf serum 
(Hyclone),  2 mM L-glutamine, 1.5 g/l sodium bicarbonate, 1 mM sodium pyruvate, 50 U/ml 
penicillin, and 50 µg/ml streptomycin (Invitrogen).  MeWo and SK-Mel-28 cell lines were 
grown in Minimum Essential Medium (MEM) supplemented with 10% fetal calf serum, 50U/ml 
penicillin, and 50µg/ml streptomycin.  Peripheral blood lymphocytes (PBL) from healthy normal 
donors were used as controls.  Paraffin-embedded archival tissue (PEAT) specimens were 
obtained from melanoma patients who underwent surgical resection at Shinshu University 
Hospital (Nagano, Japan) between 1999 and 2009.  All of these specimens were initially assessed 
by surgical pathologists at Shinshu University Hospital and diagnosed as melanoma. 
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Quantitative Real-time (qRT)-PCR assay.  Total RNA was extracted from cell lines and 
PBL specimens using Tri-Reagent (Molecular Research Center Inc).  The THAP5 primer 
sequences used were: 5’- GAAAGGTGCACGCAAAGTTAAT-3’ (forward); 5’- 
CAGGAGTAAAATGGTCACTACATAGAA-3’ (reverse).  The glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) primer sequences were: 5’- CCATGTTCGTCATGGGTGT -3’ 
(forward); 5’- CCAGGGGTGCTAAGCAGTT -3’ (reverse).  For cell lines and PBL specimens, 
reverse transcription (RT) reactions were performed using Moloney murine leukemia virus RT 
(Promega) with oligo-dT primer.  The qRT-PCR assay was performed with the LightCycler 
System and Universal Probe Library Set, Human (Roche Applied Science) using 250 ng of total 
RNA.  Specific plasmid controls of THAP5 and GAPDH were synthesized as described 
previously [73], and standard curves for each gene were generated with a threshold cycle of six 
serial dilutions of plasmid templates (106–101 copies). THAP5 expression was calculated as a 
ratio of THAP5 /GAPDH copy numbers. 
Immunohistochemistry.   Immunohistochemistry was performed on formalin-fixed, paraffin 
embedded sections from primary and metastatic melanoma tissues.  After deparaffinization, 
endogenous peroxidase was quenched with peroxidase block (Fisher Scientific).  For antigen 
retrieval, the sections were boiled using microwave for 20 minutes in 10 mmol/L citrate buffer 
(pH 6.0), and exposed to blocking solution (Protein Block Serum-Free, DakoCytomation).  The 
sections were incubated with polyclonal anti-THAP5 antibody for 60 minutes.  For 
immunohistochemical detection, HRP-labeled anti-rabbit immunoglobulin antibodies (DAKO 
EnVision+ System, HRP, DakoCytomation) was used (AEC + Substrate-Chromogen, 
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DakoCytomation).  Sections were counterstained via Gill’s hematoxylin (Fisher Scientific), and 
then mounted [74].  
Sub-cellular localization of THAP5 protein.   To investigate the subcellular localization 
of the THAP5 protein,
 
the full-length cDNA (aa 1-395) was cloned in frame into EGFP-
C1
 
vector (Clontech).  MeWo cells were grown
 
on glass cover slips in 12-well plates.  
Approximately 60% confluent
 
cells were transiently transfected with 1 µg of the GFP-THAP5 
plasmid using Lipofectamine 2000 Transfection Reagent
 
(Invitrogen).  Twenty-four hours after 
transfection, cells were
 
washed and fixed in 4% paraformaldehyde, permeabilized with
 
0.2% 
Triton X-100.  The cover slips were then washed
 
and placed on microscope slides using 
mounting
 
solution with DAPI to stain the nucleus.  Slides were observed using a LSM510 
Confocal laser-scanning
 
microscope (Zeiss).  
Western blot analysis of THAP5 protein expression.   Cell lysates were prepared using 
RIPA buffer (150 mM NaCl, 50 mM TrisHCl, pH 7.5, 1% Nonidet P-40, 0.25% deoxycholic 
acid sodium salt) containing the protease-inhibitor cocktail (Roche) and resolved by SDS-PAGE. 
They were then electro-transferred onto a polyvinylidene difluoride (PVDF) membrane and 
probed with polyclonal THAP5
 
antibody at a 1: 5000 dilution followed by secondary goat anti-
rabbit horseradish peroxidase conjugated antibody [72]. The immunocomplex was visualized 
using enhanced chemiluminescence (Pierce).  
Cell death assays.   MeWo cells
 
were grown in six-well plates in the appropriate medium 
until
 
they reached 90% confluency followed by treatment for 10h with increasing concentrations 
of cisplatin (1mM, 5mM, 10mM and 15mM respectively).  For UV-irradiation, cells were treated 
for 10h with increasing doses of UVC (25 mj/cm
2
, 30 mj/cm
2
, 35 mj/cm
2
, 40 mj/cm
2
 and 50 
40 
 
mj/cm
2
 respectively) using a Spectroline UV crosslinker (254nm) [75, 76].  Cells were detached 
with 1x Trypsin-EDTA (Gibco) and washed twice with
 
ice-cold PBS.  One-half of them were 
used for Western blot analysis,
 
and the rest for apoptotic assay.  Western Blot analysis 
was
 
performed as described.  The apoptotic assay was performed
 
according to BD Biosciences 
protocol.  Briefly, cells were suspended
 
in 1x binding buffer and stained with Annexin V 
(apoptotic cell)
 
and 7-amino-actinomycin D (7-AAD for necrotic cells).  Samples
 
were analyzed 
on a FACS Calibur Flow Cytometer (BD Biosciences) [37]. For the other apoptotic assay, 
MeWo cells were transfected with GFPC1 (control) and GFPC-THAP5 plasmids.  Thirty six 
hours after transfection, cells were treated with 50mj/cm
2
 of UVC.  10 hours following UVC 
treatment the cells were stained with Annexin V and 7-AAD.  Approximately ten thousand GFP 
positive cells were counted the percentage of apoptotic cells estimated [72].  
Electrophoretic Mobility Shift Assay (EMSA).   THAP5 DNA-binding assays were 
performed as described previously [77, 78]. Briefly, nuclear extracts were prepared from 
cultured MeWo and NIH3T3 cells in hypertonic buffer (20 mM HEPES, pH 7.9, 420 mM NaCl, 
1 mM EDTA, 1 mM EGTA, 20% glycerol, 20 mM NaF, 1 mM Na3VO4, 1 mM Na4P2O7, 1 mM 
DTT, 0.5 mM PMSF, 0.1 mM aprotinin, 1 mM leupeptin, 1 mM antipain).  Extracts containing   
3 g of total protein were incubated with a double-stranded 32P-radiolabeled WT oligonucleotide 
probe (5’-TGCCTGGTGCAAGTAACT) and mutant probe (5’-TGCCTGGTACACGTAACT).  
Protein-DNA complexes were resolved by non-denaturing polyacrylamide gel electrophoresis 
(PAGE) and detected by autoradiography. 
Cyclic Amplification and Selection of Targets (CASTing).   The CASTing procedure 
described by Wright et al was modified to select for the THAP5 binding site [79, 80]. A 
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randomized DNA template, 5’-TGG GCA CTA TTT ATA TCA A-N25- AAT GTC GTT GGT 
GGC CC-3’ (where N25 is a 25-base sequence of randomly inserted nucleotides) was 
synthesized and amplified with the primers 5’-
ACCGCAAGCTTGGGCACTATTTATATCAAC-3’ and 5’-GGTCTAGAGGGC 
CACCAACGACAT T-3’ in a PCR reaction.  PCR cycling conditions used were: 94oC for 2 
minutes, 30 cycles of 94
o
C (20 sec), 50
o
C (20 sec) and 72
o
C (20 sec), with a final extension at 
72
o
C (10 min).  Approximately 6l of MeWo cell extract was incubated with the PCR product 
for 30 minutes in 100 l of binding buffer (20 mM Tris, pH 7.5; 100 mM NaCl; 0.05% NP40; 
0.5 mM EDTA; 100 μg/ml BSA; 50 μg/ml Poly dI-dC; 5μg/μl single stranded salmon sperm 
DNA) at RT.  This was followed by addition of THAP5 specific antibody and Protein G-agarose 
beads.  After 30 minute incubation, the mixture was washed five times in 100 l of NT2 buffer 
(20 mM Tris, pH 7.5; 100 mM NaCl; 0.05% NP40) [71].  Beads were resuspended in 100 μl of 
H2O, and THAP5 bound DNA was purified by phenol/chloroform extraction and ethanol 
precipitation and then resuspended in 10 μl of H2O.  Two microliters of DNA isolated from the 
first round of THAP5 binding were used in a second round of PCR amplification and purification 
using the same conditions.  After seven rounds of PCR amplification (with reduced number of 
PCR cycles for the next round of CASTing), the oligonucleotides enriched for THAP5 DNA 
binding site were into the pGEM-T Easy vector (Promega).  Twenty five randomly selected 
clones were sequenced and analyzed using the Multiple EM for Motif Elicitation (MEME) 
software (meme.sdsc.edu). 
Bioinformatics Analysis.   The software tool MEME was applied to the 25 sequences 
generated from CASTing.  The first motif that was found was much more significant than other 
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reported motifs, with p-value at least 400 times smaller.  By using the consensus of this motif, 
GTGNAANNAAC, the upstream 1kb region plus 5' UTR of cell cycle genes that are reportedly 
involved in G2/M transition were scanned according to methods described in [81]. The repeats in 
these sequences were removed by Repeat Masker tool (http://www.repeatmasker.org/).  A total 
of 20 G2/M cell cycle genes were used as input and by allowing one nucleotide mismatch, 15 
genes were found to contain at least one instance of to the consensus.  
Reporter Gene Studies.   293T cells were seeded into 48-well plates to be 50-70% confluent 
the next day.  Cells were transfected with Gal4 TK-Luc reporter and pRL-SV40 Renilla 
luciferase (Promega), Gal4 DNA-binding protein (DBD) alone, Gal4 DBD-THAP5, or Gal4 
DBD-THAP7 in increasing concentrations (0ng, 5ng, 25ng) using Lipofectamine 2000 
(Invitrogen).  PCDNA3 was used to maintain the total concentration of transfected DNA [70]. 
Cells were lysed after 48 h and luciferase activity was measured according to the manufacturer's 
instructions (Promega).   
Mutation Analysis.   Three exon regions corresponding to THAP5 were amplified by PCR 
from cDNA obtained from several melanoma cell lines, primary melanocytes and metastatic 
melanoma samples.  The following specific primers were used for Exon1 (677 bp): Forward 5’- 
GAGTCGACAGACGAGGCGG -3’, Reverse 5’- CATTCCGGGCCTCAGTTTCC -3’; Exon2 
(386 bp): Forward 5’- CCTCTTGTAGTACTTACTTGAG -3’, Reverse 5’- 
CTCTCCCACCTGATCACCTG -3’; and Exon3 (1200 bp): Forward 5’- 
GCTTGGCCAGTGTACTACTC -3’, Reverse 5’- CTCTCCAGCCCAACTCTCTG -3’.  
Following amplification, the PCR products were sequenced and analyzed by ClustalW alignment 
software.  
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Statistical analysis.   All quantitative data are expressed as mean ±SD. Differences among 
groups were analyzed by one-way analysis of variance (ANOVA) followed by Tukey’s Post-hoc 
test.  A value of P<0.05 was considered significant.  
Results 
Expression of THAP5 in melanoma cells/tissues .  THAP5 is highly expressed in the 
human heart, however the lack of availability of human cardiomyocyte cell lines restricts the 
experiments we can perform to characterize the protein.  This prompted us to use a different 
system to study the function of THAP5.  We originally isolated THAP5 from a melanocyte 
cDNA library.  Before we proceeded with the use of melanoma cells as a model system, we 
performed RT-PCR analysis on several cell lines including melanoma and some other cancer 
cells along with normal kidney cells taken as control.  We found that THAP5 is highly expressed 
in some of the melanoma cell lines and not expressed in normal kidney cells (Figure 10A).  We 
obtained human primary and metastatic melanoma tissues and used THAP5 antibody to probe 
these tissues for THAP5 expression.  We found that THAP5 shows high levels of staining in 
both primary and metastatic melanoma (Figure 10B).  
Sub-cellular localization of the THAP5 protein.   We have previously shown that 
THAP5 is localized in the nucleus in Hela cells [72]. To verify that THAP5 has a similar 
subcellular location in melanoma, we cloned the cDNA sequence corresponding to the full-
length THAP5 protein into the GFPC1 vector.  The GFP-THAP5 vector was transfected into 
MeWo cells and 24 hours later the subcellular localization of the protein was observed using a 
Confocal microscope as previously described [72].  Figure 11 shows that, the full-length GFP-
THAP5 protein is exclusively localized in the cell nucleus but is excluded from the nucleoli. 
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THAP5 protein is induced in melanoma cells upon UV treatment .   In order to 
investigate whether THAP5 protein is regulated during apoptosis, MeWo cells were treated with 
increasing doses of UVC and subsequently cell death was measured by Annexin V staining and 
Flow Cytometry [72].  THAP5 protein level was monitored by Western blot analysis of cell 
extracts, following UVC treatment and was found to be significantly induced in cells in a dose 
dependent manner (Fig. 12 A, B).  THAP5 induction corresponded with increased apoptosis, 
both under conditions of increasing doses of UV and increasing time points.  (Fig. 12 C, D).  
Similar result was obtained using another melanoma cell line Sk-Mel28.  
THAP5 protein level dramatically increases in MeWo cells following cisplatin 
treatment.   Cisplatin is another chemical that is known to activate DNA damage pathways.  In 
order to investigate whether cisplatin causes a change in levels of THAP5, MeWo cells were 
treated with increasing doses of cisplatin and cell death was measured by Annexin V staining 
and Flow Cytometry [72].  THAP5 protein levels were monitored by Western blot analysis of 
cell extracts and found to be significantly increased in cells in treated with increasing doses of 
cisplatin.  This induction also correlated with a corresponding increase in percentage of apoptotic 
cells (Figure 13).  Similar results were obtained using another melanoma cell line SK-Mel28.   
THAP5 sensitizes cells to UV induced cell death .  To test whether THAP5 is 
proapoptotic or cytoprotective, MeWo cells were transfected with GFPC1 (control) and GFPC-
THAP5 plasmids.  Thirty six hours after transfection, cells were treated with increasing doses of 
UVC.  10 hours following UVC treatment the cells were stained with Annexin V and 7-AAD.  
Among the GFP-positive cells, the percentage of apoptotic cells was estimated.  We found that in 
cells overexpressing GFP-THAP5, there was increased cell death compared to those expressing 
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GFP alone (Figure 14).  This clearly shows that THAP5 sensitizes MeWo cells to UVC induced 
apoptosis [37, 72].  
THAP5 can repress transcription of a reporter gene.  THAP proteins are reportedly 
nuclear transcription factors with the ability to directly regulate expression of target genes.  In 
fact, transcriptional regulation activity has been shown before in THAP1, THAP7 and THAP11 
[43, 58, 60, 70]. Therefore, we expected THAP5 to be such a transcription regulator based on 
amino acid sequence similarity with the rest of proteins of the THAP-family.  Since we do not 
know the target genes that might be regulated by THAP5, we used a transcription repression 
system that targets the Gal4-THAP5 to a reporter gene containing four Gal4 DNA binding sites.  
Gal4-THAP5 was able to repress the transcription of Gal4 reporter gene (Figure 15).  As a 
positive control for these experiments we used Gal4-THAP7 previously shown to be a potent 
repressor of transcription when used in the same system [70]. Gal4-THAP5 repressor activity 
was not as effective as the THAP7 suggesting these two proteins might have distinctly different 
functions. 
Mutation Analysis of THAP5 gene.   THAP5 is known to arrest cells at G2/M phase of the 
cell cycle [72].  However, it is also highly expressed in several cancer cell lines and tissues in 
very high levels.  We wanted to test if the THAP5 gene is mutated.  So using specific primers, 
we amplified the three different exons of THAP5 from cDNA obtained from several obtained 
from several melanoma cell lines, primary melanocytes and metastatic melanoma tissues and 
sequenced them.  However,   we found no mutations in THAP5. This suggests that THAP5 is 
highly expressed in melanoma cell lines but not degraded and this could account for some unique 
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function in cancer cells.  Figure 16 shows a schematic diagram representing the three exons of 
THAP5 gene.  
Characterization of THAP5 binding site.   THAP5 has an atypical zinc finger domain 
(THAP domain) at its amino terminus which has been shown to be a sequence-specific DNA-
binding domain in THAP1 and mouse homolog of THAP11 (Ronin) [44, 71]. Based on this 
information, we expected THAP5 to bind to a specific DNA sequence.  To determine whether 
the THAP domain of THAP5 possesses sequence-specific DNA-binding activity and identify a 
consensus target-binding site, we used a modified PCR-based approach, CASTing (Cyclic 
Amplification and Selection of Targets) [79, 80].  We synthesized an approximately 100 bp 
random oligonucleotide using specific primers.  This oligonucleotide pool was mixed with 
MeWo cell extract to permit the formation of THAP5/DNA complexes and then 
immunoprecipitated with Protein-G agarose beads and anti-THAP5 polyclonal antibody.  The 
protein-DNA complexes were washed and then re-amplified.  This process was repeated six 
times to enrich for oligonucleotides bound to THAP5 and after the seventh round, the PCR 
product was cloned into suitable vector (described in methods) and sequenced.  Figure 17 A 
shows a consensus DNA binding site specific to THAP5.  
DNA-binding site specificity of THAP5.   To confirm the binding of THAP5 to the 
consensus DNA binding site, we performed electrophoretic mobility shift assays (EMSA) [77, 
78].  We used labeled oligonucleotides containing the THAP5 consensus sequence (WT 5’-
TGCCTGGTGCAAGTAACT), resolved the protein-DNA complexes by non-denaturing 
polyacrylamide gel electrophoresis (PAGE) and detected the bands by autoradiography.  Figure 
17B shows specific binding of THAP5 to the consensus sequence in MeWo extracts.  Use of a 
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THAP5 specific antibody significantly reduced the binding of the complex.  In addition, we do 
not see any binding of THAP5 in NIH3T3 mouse extracts (which lack THAP5 protein), showing 
that the DNA binding site is highly specific to THAP5.  We also used 100 molar excess of cold 
probe (WT and mutant) and found that the binding of THAP5 was abolished completely.  We 
mutated the consensus DNA binding site by modifying the invariable G and A nucleotides at 
positions 3 and 6, and found that the binding of THAP5 to the mutant probe was significantly 
diminished (Fig 17C).  
Identification of THAP5 binding site in promoter of G2/M genes.   In previous 
studies, THAP1, THAP11 and the mouse homolog of THAP11 (Ronin) were shown to bind a 
specific DNA sequence and regulate transcription of specific genes RRM1, c-Myc and HCF-1 
respectively [44, 60, 71]. We know THAP5 is present exclusively in the cell nucleus and ectopic 
expression of THAP5 induces G2/M arrest in transfected cells [72].  Therefore, if THAP5 is 
indeed a transcription factor, one of its functions will be direct regulation of genes involved in 
cell-cycle.  Based on this information and using the consensus THAP5 binding motif, 
GTGNAANNAAC, nucleotides spanning the 1kb region upstream of the promoters including 5' 
UTR of known cell cycle genes involved in G2/M transition [81] were scanned using specific 
software described in the methods section.  A total of 20 G2/M genes were used as input and by 
allowing one nucleotide mismatch, 15 promoters were found to contain at least one instance of 
the consensus (shown in figure 16) (described in methods).  
Discussion 
THAP proteins are characterized by the presence of a THAP domain at the N-terminus with 
specific conserved residues and these include, a C2CH zinc finger motif, three other residues 
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(P26, W36, F58) and a C-terminal AVPTIF box (Ala-Val-Pro-Thr-Ile-Phe), which have been 
shown to be essential for the DNA binding activity of these proteins [38]. Abolishing any of 
these key residues eliminates DNA binding activity [44, 82]. In this study, we have expanded our 
studies on THAP5, one of the twelve human THAP proteins.  For this purpose, we used 
melanoma cells because we originally isolated THAP5 as an interactor of Omi/HtrA2 using a 
melanocyte library and it is also expressed in melanocytes /melanoma.  
We performed RT-PCR analysis of several cancer cell lines and found THAP5 to be highly 
expressed in several melanoma cell lines but not in normal cells.  Moreover primary and 
metastatic melanoma tissues also show high levels of expression of THAP5.  This raises a 
question as to why a protein which is involved in cell cycle arrest would be highly expressed in 
cancer cells.  This could be the result of some mutation in THAP5 gene in these cells.  To test 
this, we performed mutation analysis of several of the melanoma cell lines and metastatic 
melanomas using PCR amplification of the three exons encoding for THAP5 gene followed by 
sequencing of the exons.  However, we found no mutations in the THAP5 gene.  This suggests 
that THAP5 plays is highly expressed but not targeted for degradation.  The stabilization of 
THAP5 could account for it function in melanoma cells and other cancers.  We have previously 
shown that THAP5 contains a nuclear localization signal able to translocate the protein to the 
nucleus of HeLa cells [72]. To verify that THAP5 is also nuclear in melanoma cells we 
transfected MeWo cells with GFP-THAP5 fusion protein.  These experiments clearly showed 
GFP-THAP is exclusively nuclear.   
Some of the THAP proteins have been implied in functions such as apoptosis and cell cycle 
control.  THAP0/DAP4 was originally identified while screening a Hela library for IFN- 
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induced apoptosis genes [57].  It is speculated that THAP0/DAP4 may promote MST1-induced 
apoptosis by enabling the colocalization of MST-1 protein with p53 [69].  Also, THAP1 has 
been shown to be a proapoptotic protein associated with promyelocytic leukemia nuclear bodies 
(PML NBs), which interacts with Par-4 and induces serum withdrawal and TNF-induced 
apoptosis [45]. Par-4 is a transcriptional regulator which is upregulated in prostate cancer cells 
undergoing apoptosis [83, 84].   Additionally, overexpression of Par-4 in neurons, prostate 
cancer and melanoma cells also sensitizes these cell types to apoptosis [43]. To investigate 
THAP5’s role during apoptosis in melanoma, we treated MeWo cells with UVC.  We used UVC 
to induce apoptosis because it is the most relevant physiological stimulus for these cells and it is 
also known to be responsible for the development melanoma cancers.  In MeWo cells, upon 
treatment with UVC, we found that THAP5 is considerably induced and this increase correlated 
with the degree of apoptosis in the cell population.  Similar results were obtained using a 
melanoma cell line, SK-Mel28.  
The induction of THAP5 in melanoma cells treated with UV could have a pro-apoptotic or 
cytoprotective function.  To test this we transfected MeWo cells with GFP-THAP5.  We 
irradiated these cells with increasing doses of UVC and found that GFP-THAP5 over-expressing 
cells were more sensitive to UVC radiation compared to cells expressing GFPC vector alone.  
This suggests that THAP5 has a proapoptotic function in melanoma cells treated with UV. 
We investigated whether UV alone can induce THAP5 or other cytotoxic chemicals known to 
cause DNA damage can have a similar effect.  For these experiments, MeWo cells were treated 
with cisplatin.  Cisplatin forms adduct with DNA and the resulting inter and intra strand 
crosslinks disrupt the structure of the DNA thereby interfering with replication and transcription 
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processes [85]. This alteration in the structure is recognized by the cellular proteins to repair 
cisplatin-induced DNA damage [85]. THAP5 protein was also induced when melanoma cells 
were treated with cisplatin in a similar manner as cells treated with UV.  These results suggest 
THAP5 is probably involved in a previously unknown pathway that gets activated by DNA 
damage leading to cell death.  
THAP proteins constitute the second largest family of zinc finger proteins after the C2CH family 
[82]. The few members that have been studied were shown to have DNA binding activity and to 
recognize specific target sequences.  THAP1 binds to an 11 nucleotide motif and Ronin (mouse 
homolog of THAP11) recognizes a slightly longer and different 15 nucleotide sequence [44, 71]. 
These findings as well as recent structural analysis has speculated that each THAP protein may 
bind to a unique DNA sequence and therefore perform a distinct function in cells where it is 
expressed [44, 71, 86].  We employed a modified protocol of the Cyclic Amplification and 
Selection of Targets (CASTing) assay and identified an 11 nucleotide consensus binding 
sequence recognized by THAP5 [79, 80].  To verify that THAP5 can bind to this sequence in 
cells we performed electrophoretic mobility shift assays (EMSA).  We confirmed the specificity 
of binding by using THAP5 specific antibody which reduced the binding significantly.  Not only 
does the probe bind to THAP5 specifically but also shows no binding in mouse nuclear extracts 
(NIH3T3) which lack THAP5.  We mutated the two nucleotides which were invariable in all 
sequences (G3 and A6) and found that the binding of THAP5 to the sequence is considerably 
reduced.  
It has been proposed that some members of the THAP family of proteins (THAP7 and HIM-17) 
play a role in chromatin regulation because of their interaction with chromatin-modifying 
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proteins [58, 70].  THAP7 has been shown to associate with histone tails, HDACs and NCoRs 
[58, 70] and act as a transcriptional repressor. HIM-17 is involved in recruitment of the 
methyltransferase activity to histone H3 [87, 88]. Ronin interacts with HCF-1, an important 
transcriptional regulator [71].  
Since there’s no information on the potential gene targets of THAP5, we first performed a 
transfected reporter gene assay.  For this assay, we used THAP5 fused to a Gal4 DNA binding 
domain and cotransfected it with a vector containing the firefly luciferase gene under the control 
of Gal4 binding sides and a control Renilla luciferase reporter.  We measured the luciferase 
activity relative to the Renilla luciferase values.  As a control for this experiment we used Gal4-
THAP7 which has already been shown to be a transcription repressor [58, 70].  Gal4-THAP5 
shows repressor activity but it was not as high as the Gal4-THAP7.  Although at this point, we 
have only demonstrated that THAP5 can function as a repressor in a heterologous system, we 
still do not know if it can repress genes in cells and under what conditions this function comes 
into play.   
Some of the THAP proteins have been shown to exert their function by acting on specific gene 
targets.  THAP1 has been shown to act on RRM1 gene, a pRb/E2F cell cycle target [43]. 
THAP11 represses c-Myc and negatively downregulates growth of cells [60]. Since we already 
know the specific DNA sequence that THAP5 binds to, we decided to look for this binding site 
in promoters of genes which are involved in G2/M transition.  The reason we did this was 
because we have previously shown that THAP5 is involved in G2/M cell cycle arrest [72]. We 
took a set of 20 known genes involved in G2/M cell cycle arrest.  Using the consensus binding 
site for THAP5 we scanned the promoter region of these genes and found the binding site in 
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several of the genes.  Of these genes, we are particularly interested in the sites that showed up 
only in human, rhesus and dog because THAP5 is not expressed in mouse/rats.  
Currently we are looking at a set of genes and using their promoter regions containing potential 
THAP5 binding sites in luciferase assays to test if THAP5 regulates their transcription.  It’ll be 
interesting to identify potential targets of THAP5 because it can provide a lot of information on 
THAP5’s functions in cells.  As a starting point, it might be worthwhile to look into HCF-1, a 
large protein involved in transcriptional control.  Previously, Ronin (mouse homolog of 
THAP11) has been shown to associate with a large HCF-1 protein containing complex, in which 
even THAP7 was pulled down [71]. Recently another group also showed that THAP1 and 
THAP3 can interact with HCF-1 and activate transcription [89].  They also showed that most of 
the THAP proteins have a HCF-1 binding motif called HBM through which they interact with 
the amino-terminal kelch domain of HCF-1.  The HBMs are always located upstream of the 
coiled-coil domains and found at similar locations in the orthologs of THAP proteins in other 
species such as zebrafish and xenopus [89].  In fact, in a yeast two hybrid screen, they showed 
that most of the THAP proteins including THAP5 can interact with HCF-1 protein.  Therefore, it 
has been proposed that interaction of THAP proteins with HCF-1 may be important for both 
transcriptional activation and repression, depending on the THAP protein involved, the cellular 
context and/or the cell cycle status [89]. 
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Figure 10.  Expression of THAP5 in melanoma cells and tissues. 
A,   qRT-PCR analysis of various cell lines showing THAP5 expression.  qRT-PCR was performed on 
several cell lines including melanoma and some other cancer cell lines with normal kidney cells as 
control.  THAP5 is highly expressed in some melanoma cell lines.  B, Immunohistochemistry staining of 
primary and metastatic melanoma tissues showing high levels of THAP5.  
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Figure 11.  Subcellular localization of the THAP5 protein in melanoma (Mewo) cells.  
Confocal images of Mewo cells transfected with GFP-THAP51-395 shows exclusive nuclear 
localization (green in A).  Nomarski/DIC images of the same cells are shown in A'.  Panel B 
shows cells with DAPI staining for the nucleus and B’ shows merged image of Panels A, B and 
A’.  
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Figure 12.  THAP5 protein is induced in MeWo cells upon UV treatment.  
A, Cell death was monitored in the treated cell populations, by Annexin V and 7-AAD staining and 
analyzed by flow cytometry; B, Cell extracts of the treated samples were prepared, followed by Western 
blot analysis of the same.  Lane 1 shows lysate from control cells; lanes 2, 3, 4, 5 and 6  show extracts 
from MeWo cells treated with increasing doses of UVC; 25mj/cm
2
, 30mj/cm
2
, 35 mj/cm
2
, 40mj/cm
2
, 50 
mj/cm
2 
respectively.  THAP5 protein level increases with time.  C, Cell death was monitored in the UVC 
treated cell populations, by Annexin V and 7-AAD staining and analyzed by flow cytometry.  D, cell 
extracts were prepared followed by Western blot analysis of the treated samples.  Lane 1 shows lysates 
from control cells; lanes 2, 3, 4, 5 and 6 show extracts from cells treated with 50 mj/cm
2 
of UVC after 4, 
6, 8 and 10 hrs respectively.  β-Actin antibody was used to verify that equal amounts of protein were 
present in each lane.  Data are means ± SD of four independent experiments. 
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Figure 13.  THAP5 protein levels increase following cisplatin treatment.  
MeWo cells were treated with increasing doses of cisplatin to induce apoptosis.  A, Cell death was 
monitored in the treated cell populations, by Annexin V and 7-AAD staining and analyzed by flow 
cytometry.  B, Cell extracts were prepared followed by Western blot analysis of the treated samples.  
Lane 1 shows lysates from control cells; lanes 2, 3, 4, and 5 show cells treated with 1mM, 5mM, 10mM 
and 15mM cisplatin for 10 hours respectively.  β-actin antibody was used to verify that equal amounts of 
protein were present in each lane.  Data are means ± SD of four independent experiments.  
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Figure 14.  Overexpression of THAP5 sensitizes cells to UV induced apoptosis. 
MeWo cells were transfected with GFPC vector and GFPC-THAP5 plasmids.  36 hours following 
transfection, cells were treated with increasing doses of UVC.  Cell death was monitored in the treated 
cell populations, by Annexin V and 7-AAD staining and GFP positive cells were counted analyzed by 
flow cytometry.  Data are mean ± SD of 3 different experiments.  
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Figure 15.  THAP5 represses transcription of a reporter gene.  
Gal4DBD-Thap5 and Gal4DBD-Thap7 were transfected separately in increasing amounts (0ng, 5ng and 
25ng respectively) into HEK-293T cells along with Gal4 MH100TK-luc reporter and a control Renilla 
luciferase reporter (pRL-SV40 Luc).  Luciferase assays were performed 48 hrs post transfection.  Values 
are reported relative to Renilla Luciferase reporter.  Data are means ± SD of four independent 
experiments.  
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Figure 16.  Schematic representation of the THAP5 gene.  
Full-length THAP5 gene contains 3 exons regions.  Exon1 is 677 base pairs (bp), Exon2 is 386 
bp and Exon 3 is 1200 bp long.  The three exon regions depicted in the figure were amplified by 
PCR from cDNA obtained from several melanoma cell lines, primary melanocytes and 
metastatic melanoma tissues.  Specific primers were used for amplification of the three exons 
followed by sequencing and analysis of the PCR products for mutations.  
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Figure 17.  Identification of a THAP5 consensus DNA-binding site.  
A, The 11-nucleotide THAP5 DNA binding site.  The oligonucleotide sequences recovered after 7 rounds 
of selection were analyzed by the motif-discovery program MEME.  B, Electrophoretic Mobility Shift 
Assay showing THAP5 binding to consensus sequence.  Lane 1, control (no extract); lane 2, MeWo 
nuclear extract; lane 3, MeWo extract with anti-THAP5 antibody; lane 4, NIH 3T3 extract; lane 5, MeWo 
extract plus 100 molar excess of cold THAP5 specific probe (WT 5’-TGCCTGGTGCAAGTAACT ) and 
lane 6, MeWo extract plus 100 molar excess of mutant probe (Mut 5’-TGCCTGGTACACGTAACT), 
incubated with 
32
P labeled wild type probe.  The protein-DNA complexes were analyzed by 
electrophoretic mobility shift assay (EMSA) as described in methods.  C, Specificity of THAP5 Binding.  
First four lanes show THAP5 binding to the labeled WT probe.  Lane 1, control (no extract); lane 2, 
MeWo nuclear extract; lane 3, MeWo extract with anti-THAP5 antibody; lane 4, NIH 3T3 extract.  Lanes 
5-6 show reduced binding of THAP5 to the labeled Mutant probe.  Lane 5, control (no extract); lane 6, 
MeWo nuclear extract; lane 7, MeWo extract with anti-THAP5 antibody; lane 8, NIH 3T3 extract. 
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Figure 18.  Identification of potential promoters containing THAP5 binding site. 
Using the consensus THAP5 binding motif, GTGNAANNAAC, nucleotides spanning the 1kb region 
upstream of the promoters including 5' UTR of known cell cycle genes involved in G2/M transition  were 
scanned using the software listed in Materials and Methods.  A total of 20 G2/M genes were scanned and 
by allowing one nucleotide mismatch, 15 genes were found to contain at least one instance of the 
consensus (shown in table).  
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CHAPTER 4: GENERAL DISCUSSION AND CONCLUSIONS 
Omi/HtrA2 is an extensively studied serine protease.  Its role as a proapoptotic protease is very 
well established however, its normal function in cells is not known [3, 5, 6, 11]. Most of the 
recent studies seem to point out to a protective function for Omi/HtrA2 [19]. Some groups 
believe it may be involved in the maintenance of cellular equilibrium.  In order to define the 
functions of a protein it is important to find out what other proteins it interacts with.  The 
interacting/partner protein sheds light on the possible pathways/ functions of the protein of 
interest.  The yeast two-hybrid system is a popular method used to isolate new protein 
interactors.  We employed this method to discover new partners of Omi/HtrA2.  Among the 
approximately 30 interactors obtained, the one of most interest to us was THAP5.  There was no 
published information on this protein.  The only known information on THAP5 was it belongs to 
a large family of transcription factors called THAP proteins [45].  All the proteins in this family 
have zinc dependent DNA binding activity and are involved in various important cellular 
functions [45].  
Through my dissertation we were able to obtain key information on the function of this novel 
THAP5 protein.  THAP5 is a 395 amino acid protein which localizes in the nucleus.  It encodes 
for an approximately 50kDa protein.  THAP5 mRNA is highly expressed in the human heart and 
some expression is seen in the brain and skeletal muscle.  It interacts with Omi/HtrA2 in yeast 
and in mammalian cells.  However, in mammalian cells, THAP5 interacts with Omi/HtrA2 only 
under conditions of apoptosis.  When cells are subjected to apoptotic stimuli, Omi/HtrA2 is 
released from the mitochondria and this creates a physiological meeting point for these two 
proteins.  Furthermore, the interaction of Omi/HtrA2 with proteins from different cellular 
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compartments has been well documented before.  We have been able to show that THAP5 can 
serve as a substrate for Omi/HtrA2 both in vitro and in mammalian cells.  The degradation of 
THAP5 can be prevented by the use of ucf-101, a specific inhibitor of Omi/HtrA2.  However, it 
is not known what the function of this degradation of THAP5 means [72].  
To explore the normal function of THAP5, we overexpressed the protein in cells and found that 
it induced cell cycle arrest at G2/M phase.  This could possibly explain the high levels of 
expression of THAP5 in the human heart which represents a terminally differentiated organ with 
very small percentage of dividing cells.  This function of THAP5 is also in agreement with some 
other proteins of the THAP family.  The most significant finding is the deregulation of THAP5 
in heart tissues from Coronary Artery Disease (CAD) patients.  This occurs in the myocardial 
infarction area (MI), where maximum damage and loss of cardiomyocytes happens.  Although 
the actual function of THAP5 in the human heart is unknown at this point, its deregulation 
coupled with the high expression levels in the human heart suggests that the protein plays a very 
important role in the development/ progression in heart disease [72].  The absence of mouse/rat 
homolog for THAP5 made studies with the proteins very difficult.  Besides, there are no human 
cardiomyocyte cell lines available.  Therefore, we decided to use melanoma cells to study the 
mechanism of THAP5 function, where we know THAP5 is expressed.  
We found that THAP5 has a proapoptotic function in melanoma cells.  THAP5 is not only 
induced upon UV and cisplatin mediated apoptosis, its overexpression also sensitizes melanoma 
cells to these apoptotic stimuli.  Through our results, we believe that THAP5 could be involved 
in a very important DNA damage/repair pathway.  This function of THAP5, we believe is 
independent of the Omi/HtrA2 pathway.  We have also identified a DNA binding site which is 
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specifically recognized by THAP5.  Although at this moment, we do not know the genes that 
THAP5 regulates, we have narrowed down a list of G2/M phase genes that potentially contain 
THAP5 binding site in the promoter region.  Identifying the gene targets of THAP5 will provide 
great insight into its function as a transcription factor.  Furthermore, THAP5 can repress the 
transcription of a reporter gene adding to the set of transcriptional repressors belonging to the 
THAP family of proteins.  In summary, our work identifies a novel cardiospecific transcription 
factor with an important role in heart disease and melanoma apoptosis.   
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